These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36205748)

  • 21. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1/2 germline missense mutations: a systematic review.
    Corso G; Feroce I; Intra M; Toesca A; Magnoni F; Sargenti M; Naninato P; Caldarella P; Pagani G; Vento A; Veronesi P; Bonanni B; Galimberti V
    Eur J Cancer Prev; 2018 May; 27(3):279-286. PubMed ID: 28277317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
    Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
    Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Metcalfe KA; Gronwald J; Tung NM; McCuaig JM; Eisen A; Elser C; Foulkes WD; Neuhausen SL; Senter L; Moller P; Bordeleau L; Fruscio R; Velsher L; Zakalik D; Olopade OI; Eng C; Pal T; Cullinane CA; Couch FJ; Kotsopoulos J; Sun P; Lubinski J; Narod SA
    Cancer; 2023 Mar; 129(6):901-907. PubMed ID: 36571512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants.
    Yao L; Sun J; Hu L; Chen J; Zhang J; Xu Y; Xie Y
    J Hum Genet; 2022 Nov; 67(11):639-642. PubMed ID: 35864222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
    Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
    Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
    Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
    Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
    Beristain E; Martínez-Bouzas C; Guerra I; Viguera N; Moreno J; Ibañez E; Díez J; Rodríguez F; Mallabiabarrena G; Luján S; Gorostiaga J; De Pablo JL; Mendizabal JL; Tejada MI
    Breast Cancer Res Treat; 2007 Dec; 106(2):255-62. PubMed ID: 17262179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
    Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
    BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline
    Mehta A; Vasudevan S; Sharma SK; Kumar D; Panigrahi M; Suryavanshi M; Gupta G
    Cancer Manag Res; 2018; 10():6505-6516. PubMed ID: 30555256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer.
    Sokolenko AP; Sultanova LV; Stepanov IA; Romanko AA; Venina AR; Sokolova TN; Musayeva HS; Tovgereeva MY; Magomedova MK; Akhmatkhanov KU; Vagapova EI; Suleymanov EA; Vasilyeva EV; Bakaeva EK; Bizin IV; Aleksakhina SN; Imyanitov EN
    Cancer Med; 2023 Feb; 12(3):3167-3171. PubMed ID: 36000185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
    Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
    Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
    Miramar MD; Calvo MT; Rodriguez A; Antón A; Lorente F; Barrio E; Herrero A; Burriel J; García de Jalón A
    Breast Cancer Res Treat; 2008 Nov; 112(2):353-8. PubMed ID: 18176857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.
    Awadelkarim KD; Aceto G; Veschi S; Elhaj A; Morgano A; Mohamedani AA; Eltayeb EA; Abuidris D; Di Gioacchino M; Battista P; Verginelli F; Cama A; Elwali NE; Mariani-Costantini R
    Breast Cancer Res Treat; 2007 Apr; 102(2):189-99. PubMed ID: 17333343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
    Zidekova D; Waczulikova I; Dolesova L; Vavrova L; Hamidova O; Lohajova Behulova R; Konecny M
    Neoplasma; 2018; 65(2):309-315. PubMed ID: 29534594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
    Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
    JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.